vs
Side-by-side financial comparison of Principal Financial Group (PFG) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $750.8M, roughly 1.0× Principal Financial Group). Insulet Corporation runs the higher net margin — 13.0% vs 0.3%, a 12.7% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 4.0%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -58.3%).
Principal Financial GroupPFGEarnings & Financial Report
Principal Financial Group, Inc. (PFG) is an American global financial investment management and insurance company headquartered in Des Moines, Iowa, United States.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
PFG vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $750.8M | $783.7M |
| Net Profit | $1.9M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 0.3% | 13.0% |
| Revenue YoY | 4.0% | 31.2% |
| Net Profit YoY | 783.0% | 0.9% |
| EPS (diluted) | — | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $750.8M | — | ||
| Q4 25 | $4.6B | $783.7M | ||
| Q3 25 | $3.7B | $706.3M | ||
| Q2 25 | $3.7B | $649.1M | ||
| Q1 25 | $3.7B | $569.0M | ||
| Q4 24 | $4.8B | $597.5M | ||
| Q3 24 | $3.0B | $543.9M | ||
| Q2 24 | $4.3B | $488.5M |
| Q1 26 | $1.9M | — | ||
| Q4 25 | $517.0M | $101.6M | ||
| Q3 25 | $213.8M | $87.6M | ||
| Q2 25 | $406.2M | $22.5M | ||
| Q1 25 | $48.1M | $35.4M | ||
| Q4 24 | $905.4M | $100.7M | ||
| Q3 24 | $-220.0M | $77.5M | ||
| Q2 24 | $353.1M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 11.2% |
| Q1 26 | 0.3% | — | ||
| Q4 25 | 11.3% | 13.0% | ||
| Q3 25 | 5.8% | 12.4% | ||
| Q2 25 | 11.1% | 3.5% | ||
| Q1 25 | 1.3% | 6.2% | ||
| Q4 24 | 19.1% | 16.9% | ||
| Q3 24 | -7.3% | 14.2% | ||
| Q2 24 | 8.2% | 38.6% |
| Q1 26 | — | — | ||
| Q4 25 | $2.30 | $1.42 | ||
| Q3 25 | $0.95 | $1.24 | ||
| Q2 25 | $1.79 | $0.32 | ||
| Q1 25 | $0.21 | $0.50 | ||
| Q4 24 | $3.92 | $1.38 | ||
| Q3 24 | $-0.95 | $1.08 | ||
| Q2 24 | $1.49 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | — | $1.5B |
| Total Assets | — | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.4B | — | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $6.2B | — | ||
| Q2 24 | $4.8B | — |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | $930.8M | ||
| Q3 25 | $3.9B | $934.9M | ||
| Q2 25 | $3.9B | $939.0M | ||
| Q1 25 | $4.3B | $1.6B | ||
| Q4 24 | $4.0B | $1.3B | ||
| Q3 24 | $3.9B | $1.4B | ||
| Q2 24 | $3.9B | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | $11.9B | $1.5B | ||
| Q3 25 | $11.7B | $1.4B | ||
| Q2 25 | $11.4B | $1.5B | ||
| Q1 25 | $11.2B | $1.3B | ||
| Q4 24 | $11.1B | $1.2B | ||
| Q3 24 | $11.2B | $1.1B | ||
| Q2 24 | $11.0B | $998.4M |
| Q1 26 | — | — | ||
| Q4 25 | $341.4B | $3.2B | ||
| Q3 25 | $334.5B | $3.0B | ||
| Q2 25 | $323.1B | $3.5B | ||
| Q1 25 | $313.0B | $3.5B | ||
| Q4 24 | $313.7B | $3.1B | ||
| Q3 24 | $322.9B | $3.0B | ||
| Q2 24 | $308.8B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.33× | 0.61× | ||
| Q3 25 | 0.34× | 0.68× | ||
| Q2 25 | 0.34× | 0.64× | ||
| Q1 25 | 0.39× | 1.21× | ||
| Q4 24 | 0.36× | 1.07× | ||
| Q3 24 | 0.35× | 1.21× | ||
| Q2 24 | 0.36× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $183.3M | ||
| Q3 25 | $1.0B | $125.7M | ||
| Q2 25 | $811.9M | $196.5M | ||
| Q1 25 | $977.3M | $63.8M | ||
| Q4 24 | $1.5B | $147.7M | ||
| Q3 24 | $1.1B | $98.5M | ||
| Q2 24 | $1.4B | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.37× | 1.80× | ||
| Q3 25 | 4.70× | 1.43× | ||
| Q2 25 | 2.00× | 8.73× | ||
| Q1 25 | 20.32× | 1.80× | ||
| Q4 24 | 1.61× | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 4.05× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PFG
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
